Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT05951959
Registration number
NCT05951959
Ethics application status
Date submitted
5/06/2023
Date registered
19/07/2023
Date last updated
6/03/2024
Titles & IDs
Public title
A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma
Query!
Scientific title
A Multicentre, Phase II, Randomised, Open-label Study to Evaluate the Efficacy of Acalabrutinib in Combination With Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma (TrAVeRse)
Query!
Secondary ID [1]
0
0
D822GC00001
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
TrAVeRse
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Mantle Cell Lymphoma (MCL)
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma
Query!
Cancer
0
0
0
0
Query!
Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Acalabrutinib
Treatment: Drugs - Venetoclax
Treatment: Drugs - Rituximab
Experimental: Acalabrutinib + Venetoclax + Rituximab - Acalabrutinib + Venetoclax + Rituximab (AVR)
Treatment: Drugs: Acalabrutinib
Investigational Product
Treatment: Drugs: Venetoclax
Investigator Product
Treatment: Drugs: Rituximab
Investigator Product
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
MRD-negative CR rate
Query!
Assessment method [1]
0
0
MRD-negative CR rate is defined as the proportion of participants who achieved MRD-negativity in peripheral blood by NGS at a threshold of 10-5 while in CR per the Lugano Classification for NHL at the end of AVR induction
Query!
Timepoint [1]
0
0
At the end of AVR induction, i.e., following completion of Cycle 13 (each cycle is 28 days)
Query!
Secondary outcome [1]
0
0
MRD-negative CR rate
Query!
Assessment method [1]
0
0
MRD-negative CR rate is defined as the proportion of participants who achieved MRD-negativity in peripheral blood by NGS at a threshold of 10-5 while in CR per the Lugano Classification for NHL at any time during the study.
Query!
Timepoint [1]
0
0
Up to approximately 67 months
Query!
Secondary outcome [2]
0
0
Overall Response Rate (ORR)
Query!
Assessment method [2]
0
0
ORR is defined as the proportion of participants with a CR or PR, as determined by the investigator.
Query!
Timepoint [2]
0
0
Up to approximately 67 months
Query!
Secondary outcome [3]
0
0
Overall Response Rate (ORR)
Query!
Assessment method [3]
0
0
ORR is defined as the proportion of participants with a CR or PR, as determined by the investigator.
Query!
Timepoint [3]
0
0
At the end of AVR induction, i.e., following completion of Cycle 13 (each cycle is 28 days)
Query!
Secondary outcome [4]
0
0
Complete Response (CR) rate
Query!
Assessment method [4]
0
0
CR rate is defined as the proportion of participants with a best response of CR.
Query!
Timepoint [4]
0
0
Up to approximately 67 months
Query!
Secondary outcome [5]
0
0
Complete Response (CR) rate
Query!
Assessment method [5]
0
0
CR rate is defined as the proportion of participants with a best response of CR.
Query!
Timepoint [5]
0
0
At the end of AVR induction, i.e., following completion of Cycle 13 (each cycle is 28 days)
Query!
Secondary outcome [6]
0
0
Duration of Response (DoR)
Query!
Assessment method [6]
0
0
The DoR is defined as the time from the date of first documented response (CR-PR) until the date of documented progression per the Lugano Classification for NHL or death (by any cause in the absence of disease progression), whichever occurs first.
Query!
Timepoint [6]
0
0
Up to approximately 67 months
Query!
Secondary outcome [7]
0
0
Time to Next Treatment (TTNT)
Query!
Assessment method [7]
0
0
TTNT or death is defined as the time from the start of AVR induction until the start of the next anti-lymphoma therapy (including local radiotherapy, unless pre-planned at baseline) or death due to any cause, whichever comes first.
Query!
Timepoint [7]
0
0
Up to approximately 67 months
Query!
Secondary outcome [8]
0
0
Progression-free Survival (PFS)
Query!
Assessment method [8]
0
0
PFS is defined as the time from the start of AVR induction until the date of documented objective disease progression or death (by any cause in the absence of progression), regardless of whether the participant withdraws from therapy or receives another anti-cancer therapy prior to progression.
Query!
Timepoint [8]
0
0
Up to approximately 67 months
Query!
Secondary outcome [9]
0
0
Event Free Survival (EFS)
Query!
Assessment method [9]
0
0
EFS is defined as the time from the start of AVR induction to any of the following events: disease progression, or initiation of systemic anti-lymphoma treatment and or unplanned radiation, or death due to any cause, whichever occurs first.
Query!
Timepoint [9]
0
0
Up to approximately 67 months
Query!
Secondary outcome [10]
0
0
Overall Survival (OS)
Query!
Assessment method [10]
0
0
OS is defined as the time from the start of AVR induction until death due to any cause.
Query!
Timepoint [10]
0
0
Up to approximately 67 months
Query!
Secondary outcome [11]
0
0
Post randomization time to first occurrence of relapse or death, EFS and TTNT in continued acalabrutinib arm compared to observation arm.
Query!
Assessment method [11]
0
0
Time to first occurrence of relapse or death is defined as the time from Cycle 15 Day 1 until date of progression per the Lugano Classification for NHL as assessed by investigator, or death due to any cause, whichever occurs first.
Event-free survival is defined as the time from Cycle 15 Day 1 until any of the following events: disease progression, or initiation of subsequent systemic anti-lymphoma treatment and/or unplanned radiation, or death due to any cause, whichever occurs first.
Time to next therapy or death is defined as the time from Cycle 15 Day 1 until the start of the next anti-lymphoma therapy (including local radiotherapy, unless pre-planned at baseline) or death due to any cause, whichever comes first.
Query!
Timepoint [11]
0
0
Yearly from Cycle 15 (each cycle is 28 days) Day 1, until 3 years after randomization
Query!
Secondary outcome [12]
0
0
Number of participants with any Adverse Events (AE), Serious Adverse Events (SAE), Adverse Event of Special Interest (AESI) and AEs leading to study treatment discontinuation or dose modification.
Query!
Assessment method [12]
0
0
Adverse events will be graded by the investigator according to the NCI-CTCAE v5.0. Each AE verbatim term will be coded to a system organ class and a preferred term using the MedDRA.
Query!
Timepoint [12]
0
0
Up to approximately 67 months
Query!
Eligibility
Key inclusion criteria
Age
1. Participant must be = 18 years or the legal age of consent in the jurisdiction in
which the study is taking place, whichever is greater, at the time of signing the
informed consent.
Type of Participant and Disease Characteristics
2. Histologically documented MCL based on criteria established by the World Health
Organization with documentation of chromosomal translocation t(11;14) (q13;q32) and/or
overexpression of cyclin D1 in association with other relevant markers (e.g., CD5,
CD19, CD20 or PAX5).
3. Clinical Stage II, III, or IV by Ann Arbor Classification and requiring treatment in
the opinion of the treating clinician.
4. At least 1 measurable site of disease per Lugano Classification for NHL (Appendix K).
The site of disease must be > 1.5 cm in the long axis regardless of short axis
measurement or > 1.0 cm in the short axis regardless of long axis measurement, and
clearly measurable in 2 perpendicular dimensions, as assessed by diagnostic quality CT
(MRI may be used for participants who are either allergic to CT contrast media or have
renal insufficiency that per institutional guidelines restricts the use of CT contrast
media).
OR Participant with leukemic non-nodal MCL presentation with mainly splenomegaly and
Bone Marrow (BM) or peripheral blood involvement.
5. Eastern Cooperative Oncology Group PS of 0, 1, or 2 and ECOG PS of 3 if poor PS is due
to lymphoma.
6. Confirmed availability of sufficient FFPE tumour samples for central laboratory
genomic profiling, including TP53 and clone identification for MRD testing.
Participants with leukemic non-nodal MCL may be enrolled with available BM tissue. For
non-nodal leukaemic MCL participants and when nodal or extranodal tissue is not easily
accessible and an invasive biopsy will cause a significant risk to the participant,
the participant can be enrolled without a tissue biopsy if MCL is confirmed by a BM
biopsy and sufficient BM biopsy and aspirate provided for TP53 testing, tumour
profiling and clone identification for MRD testing.
7. Adequate organ and bone marrow function.
Sex and Contraceptive/Barrier Requirements 8 Male and/or female Contraceptive use by males
or females should be consistent with local regulations regarding the methods of
contraception for those participating in clinical studies.
1. Male participants:
- Male participants with a female partner of child-bearing potential should use a
condom from enrolment, throughout the study until 90 days following the last dose of
venetoclax or rituximab, whichever is longer.
- For non-pregnant potentially childbearing partners, contraception recommendations
should also be considered. A male participant must agree to refrain from sperm
donation throughout the study until 90 days following the last dose of venetoclax or
rituximab, whichever is longer.
2. Female participants:
- Women of childbearing potential must have negative serum pregnancy test result
prior to the start of study intervention (Cycle 1 Day 1) and agree to abstain
from breastfeeding during study participation and at least 12 months after the
last drug administration.
- Female participants of childbearing potential who are sexually active with a
nonsterilized male partner must agree to use one highly effective form of birth
control from enrolment, throughout the study and at least 2 days after the last
dose of acalabrutinib, at least 6 months after the last dose of venetoclax, and
at least 12 months after the last dose of rituximab, whichever is longer.
Informed Consent 9 Capable of giving signed informed consent which includes compliance with
the requirements and restrictions listed in the ICF and in this protocol 10 Provision of
signed and dated written Optional Genetic Research Information informed consent prior to
collection of samples for optional genetic research that supports the Genomic Initiative.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Medical Conditions
1. Active CNS involvement by lymphoma or leptomeningeal disease
2. Current or previous active malignancies requiring anticancer therapy except:
- adequately treated basal cell or squamous cell skin cancer
- in situ cancer
- history of cancer with no evidence of recurrence for = 2 years before enrolment
- local radiotherapy field that does not overlap with sites of MCL disease and the
participant had recovered from any toxicity.
- anti-hormonal therapies are permitted after discussion with the sponsor's medical
monitor
3. Participants for whom the goal of therapy is tumour debulking before ASCT
4. Any severe or life-threatening illness, medical condition (e.g., uncontrolled
hypertension, bleeding diathesis), or organ system dysfunction which, in the
investigator' opinion, could compromise the participant safety, interfere with the
absorption or metabolism of study intervention (acalabrutinib, rituximab, venetoclax)
or put the study outcomes at undue risk
5. Clinically significant cardiovascular disease such as uncontrolled or untreated
symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6
months of screening, or any Class 3 (moderate) or Class 4 (severe) cardiac disease as
defined by the New York Heart Association Functional Classification, or QTc > 480 msec
at screening. Exception: Participants with controlled, asymptomatic atrial
fibrillation during screening may enroll.
6. Any active uncontrolled infection (bacterial, viral, fungal, or other infection),
defined as exhibiting ongoing signs/symptoms related to the infection and without
improvement, despite appropriate antibiotics or other treatment, which in the
investigator's opinion makes it undesirable or pose a safety risk for the participant
to participate in the study.
7. HIV infection. As per standard of care, results of HIV serology should be known prior
to start of study intervention. In the acute situation, registration may occur without
the results of the HIV serology but must be available prior to start of study
intervention
Excluded Participants: Participants with active HIV infection (i.e., with detectable
viral load by PCR) are excluded.
Included Participants: HIV-positive participants receiving anti-retroviral treatment
with undetectable viral load by PCR may be enroled following discussion with the
participant's HIV physician and the sponsor medical monitor. Potential interactions
between anti-retroviral medications and study interventions should be considered.
8. Serologic status reflecting active hepatitis B or C. As per standard of care, results
of hepatitis serology should be known prior to start of study intervention. In the
acute situation, enrolment may occur without the results of the hepatitis serology but
must be available prior to start of study intervention.
(a) Participants who are HBsAg positive or hepatitis B PCR positive will not be
eligible.Participants who are anti-HBc antibody positive and who are HBsAg negative
will need to have a negative PCR result before enrolment. Participants who have
protective titres of HBsAb after vaccination will be eligible.
(b) Participants who are hepatitis C antibody positive and are HCV-PCR positive will
not be eligible.
9. History or ongoing confirmed progressive multifocal leukoencephalopathy.
10. History of stroke or intracranial haemorrhage within 6 months prior to the first dose
of study intervention (Cycle 1 Day 1).
11. Uncontrolled autoimmune haemolytic anaemia or idiopathic thrombocytopenic purpura.
12. Active bleeding from a gastrointestinal ulcer, except incidental finding identified on
endoscopy that is attributable to MCL
13. Participants with a known hypersensitivity to acalabrutinib, venetoclax, or rituximab
or any of the excipients of the product.
14. Known allergy to uric acid lowering agents (e.g., xanthine oxidase inhibitors or
rasburicase)
15. Severe prior reactions to monoclonal antibodies
16. Known glucose-6-phosphate dehydrogenase deficiency
17. Malabsorption syndrome, disease significantly affecting gastrointestinal function,
resection of the stomach, extensive small bowel resection that is likely to affect
absorption, symptomatic inflammatory bowel disease, partial or complete bowel
obstruction, or gastric restrictions and bariatric surgery, such as gastric bypass or
inability to swallow the formulated product (tablets).
18. Currently pregnant (confirmed with positive pregnancy test) or breast feeding
Prior/Concomitant Therapy
19. Any prior therapies for the treatment of MCL
20. Requiring continued treatment with a strong CYP3A4 inhibitor/inducer or its use within
7 days prior to the first dose (Cycle 1 Day 1) of acalabrutinib or venetoclax 21
Requiring continued anticoagulation with warfarin or equivalent vitamin K antagonists
(e.g., phenprocoumon). Exceptions are DOACs rivaroxaban, apixaban, edoxaban and
dabigatran
22 Requiring ongoing immunosuppressive therapy, including systemic or enteric
corticosteroids except:
- Topical or inhaled corticosteroids or low-dose oral steroids (= 20 mg of prednisone or
equivalent per day) as a therapy for comorbid conditions
- Short courses of glucocorticoids in excess of 20 mg prednisone for no more than 14
days for comorbid conditions.
- Systemic use of corticosteroids as a prephase to control MCL manifestations
23 Received major surgery (excluding placement of vascular access or for diagnosis)
within 28 days of first dose of study intervention (Cycle 1 Day 1) 24 Receipt of live,
attenuated vaccine within 28 days before the first dose of study intervention (Cycle 1
Day 1) (except COVID-19 vaccine).
See Section 6.9, for lists of prohibited (Table 15) and restricted (Table 16) concomitant
medications.
Prior/Concurrent Clinical Study Experience 25 Concurrent participation in another clinical
study
Other Exclusions 26 Involvement in the planning and/or conduct of the study (applies to
both AstraZeneca staff and/or staff at the study site).
27 Judgment by the investigator that the participant should not participate in the study if
the participant is unlikely to comply with study procedures, restrictions, and
requirements.
28 Previous enrolment in the present study.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
N/A
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
13/12/2023
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
17/01/2029
Query!
Actual
Query!
Sample size
Target
100
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
Research Site - Heidelberg
Query!
Recruitment hospital [2]
0
0
Research Site - Kogarah
Query!
Recruitment hospital [3]
0
0
Research Site - Melbourne
Query!
Recruitment hospital [4]
0
0
Research Site - Nedlands
Query!
Recruitment hospital [5]
0
0
Research Site - Sydney
Query!
Recruitment postcode(s) [1]
0
0
3084 - Heidelberg
Query!
Recruitment postcode(s) [2]
0
0
NSW 2217 - Kogarah
Query!
Recruitment postcode(s) [3]
0
0
3004 - Melbourne
Query!
Recruitment postcode(s) [4]
0
0
6009 - Nedlands
Query!
Recruitment postcode(s) [5]
0
0
2109 - Sydney
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Florida
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Kansas
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
New Jersey
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
New York
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Ohio
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Pennsylvania
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Tennessee
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Texas
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Wisconsin
Query!
Country [11]
0
0
Brazil
Query!
State/province [11]
0
0
Goiania
Query!
Country [12]
0
0
Brazil
Query!
State/province [12]
0
0
Porto Alegre
Query!
Country [13]
0
0
Brazil
Query!
State/province [13]
0
0
Rio de Janeiro
Query!
Country [14]
0
0
Brazil
Query!
State/province [14]
0
0
Salvador
Query!
Country [15]
0
0
Brazil
Query!
State/province [15]
0
0
Sao Paulo
Query!
Country [16]
0
0
Brazil
Query!
State/province [16]
0
0
São Paulo
Query!
Country [17]
0
0
Canada
Query!
State/province [17]
0
0
Alberta
Query!
Country [18]
0
0
Canada
Query!
State/province [18]
0
0
British Columbia
Query!
Country [19]
0
0
Canada
Query!
State/province [19]
0
0
Nova Scotia
Query!
Country [20]
0
0
Canada
Query!
State/province [20]
0
0
Ontario
Query!
Country [21]
0
0
Canada
Query!
State/province [21]
0
0
Quebec
Query!
Country [22]
0
0
Canada
Query!
State/province [22]
0
0
Saskatchewan
Query!
Country [23]
0
0
Poland
Query!
State/province [23]
0
0
Gdynia
Query!
Country [24]
0
0
Poland
Query!
State/province [24]
0
0
Kraków
Query!
Country [25]
0
0
Poland
Query!
State/province [25]
0
0
Warszawa
Query!
Country [26]
0
0
Spain
Query!
State/province [26]
0
0
Barcelona
Query!
Country [27]
0
0
Spain
Query!
State/province [27]
0
0
Madrid
Query!
Country [28]
0
0
Spain
Query!
State/province [28]
0
0
Santiago De Compostela (A Coruña)
Query!
Country [29]
0
0
United Kingdom
Query!
State/province [29]
0
0
Birmingham
Query!
Country [30]
0
0
United Kingdom
Query!
State/province [30]
0
0
Gloucester
Query!
Country [31]
0
0
United Kingdom
Query!
State/province [31]
0
0
London
Query!
Country [32]
0
0
United Kingdom
Query!
State/province [32]
0
0
Norwich
Query!
Country [33]
0
0
United Kingdom
Query!
State/province [33]
0
0
Nottingham
Query!
Country [34]
0
0
United Kingdom
Query!
State/province [34]
0
0
Plymouth
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
AstraZeneca
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
TrAVeRse is a multicentre, open-label, randomised, Phase II study of AVR in treatment naïve
MCL participants. The primary objective will be to assess the rate of MRD-negative CR at end
of induction after completing 13 cycles of AVR. Participants achieving an MRD-negative CR at
the end of AVR induction will be randomised to continued acalabrutinib or observation.
Participants who progress during observation may receive retreatment with acalabrutinib
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT05951959
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
AstraZeneca Clinical Study Information Center
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
1-877-240-9479
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT05951959
Download to PDF